Investment analysts at Laidlaw started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Thursday. The brokerage set a “buy” rating and a $18.00 price target on the biopharmaceutical company’s stock. Laidlaw’s price target suggests a potential upside of 122.77% from the stock’s current price.
A number of other research firms have also recently commented on MRNS. ValuEngine cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, JMP Securities reaffirmed an “outperform” rating and set a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
Marinus Pharmaceuticals (MRNS) opened at $8.08 on Thursday. Marinus Pharmaceuticals has a one year low of $0.82 and a one year high of $8.90.
Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.02.
A number of hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new position in Marinus Pharmaceuticals during the 3rd quarter valued at approximately $128,000. Citadel Advisors LLC increased its holdings in shares of Marinus Pharmaceuticals by 327.8% in the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 39,371 shares in the last quarter. Susquehanna International Group LLP bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth $503,000. EAM Investors LLC bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth $554,000. Finally, Iguana Healthcare Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth $1,027,000. 49.77% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Marinus Pharmaceuticals (MRNS) Research Coverage Started at Laidlaw” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/14/marinus-pharmaceuticals-mrns-research-coverage-started-at-laidlaw.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.